Generics triumph in anti-inflammatory patent battle


Pfizer has settled a long-running patent dispute with generics heavyweights Teva and Actavis, which will allow them to produce generic versions of Pfizer's non-steroidal anti-inflammatory drug Celebrex (celecoxib) in the US.

The deals allow Teva and Actavis to launch their generic versions of the selective COX-2 inhibitor in December 2014, or potentially earlier under certain circumstances. Both companies have filed for approval with the US Food and Drug Administration, and will jostle for ‘first to file’ priority, which under US law will grant 180 days’ exclusivity for generic versions from the successful company.

The settlement follows a prolonged back-and-forth skirmish, with a US court invalidating one of Pfizer’s patents, only for it to be reinstated on appeal. But a successful challenge from Actavis knocked it back down again. By settling the dispute, Pfizer has bought itself seven months extra exclusivity, while allowing the generics companies to enter the market 11 months earlier than they would have done had the patent stood.


Related Content

Generics giants jostle over pain drug

4 June 2014 Business

news image

Mylan and Actavis contest Teva’s generic celecoxib exclusivity

India green lights production of patented cancer drug

20 March 2012 News and Analysis

news image

For the first time India has invoked a 'compulsory licence' clause to cut the cost of a patented anti-cancer drug

Most Read

No-frills coats set a trend for designer viruses

26 August 2014 Research

news image

An artificial protein that self-assembles around and protects DNA could be ideal for gene therapy, nanomachines and synthetic...

Rigid molecular wires make electrons fly

29 August 2014 Research

news image

Organic wires conduct electrons 800 times faster than other molecular counterparts by letting them hitch a ride on a vibratio...

Most Commented

Rigid molecular wires make electrons fly

29 August 2014 Research

news image

Organic wires conduct electrons 800 times faster than other molecular counterparts by letting them hitch a ride on a vibratio...

Concerns over chemical treatment of reclaimed fracking fluid

29 August 2014 Research

news image

Current recycling procedure may do more harm than good